Balasubramanian said IKS Health plans to scale operations while maintaining margins in the early-to-mid 30% range and increasing investments in artificial intelligence (AI) solutions.
For the full interview, watch the accompanying video
IKS Health’s net debt is at about $26 million as of the end of the last fiscal year, and the company aims to return to similar levels by FY30 even after funding the acquisition.
She said IKS’s artificial intelligence and R&D spending in the January-March 2026 quarter was about 5% of revenue and is expected to grow alongside revenue going forward. The company continues to benefit from technology-led operating leverage.
Also Read | India may face another year of weak earnings growth, says Emmer Capital CEO
Most of IKS’ contracts remain outcome-based, where revenues are linked to customer performance. “Risk and reward are commensurate. If patient footfalls go up, so does the money we make,” Balasubramanian said.
The company further said customer rationalization after the acquisition of AQuity Solutions was intentional and may continue for another couple of quarters as it exits smaller accounts with limited growth potential.
The company, which has a current market capitalization of ₹28,795.98 crore, has seen its shares remain flat over the last year.
Catch all the latest updates from the stock market here
